Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination
Purpose: Palbociclib is a selective cyclin-dependent kinase 4/6 inhibitor approved for metastatic ER+/HER2- breast cancer. Preclinical evidence suggests a possible synergistic effect of palbociclib when combined with radiation therapy (RT); however, the toxicity of this pairing is unknown. We report...
Main Authors: | Mudit Chowdhary, MD, Neilayan Sen, MD, Akansha Chowdhary, MD, Lydia Usha, MD, Melody A. Cobleigh, MD, Dian Wang, MD, PhD, Kirtesh R. Patel, MD, Parul N. Barry, MD, Ruta D. Rao, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-07-01
|
Series: | Advances in Radiation Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2452109419300417 |
Similar Items
-
Variations in Resources Among Radiation Oncology Residency Programs in the United States
by: Toms Vengaloor Thomas, MD, et al.
Published: (2021-01-01) -
A National Survey of Radiation Oncology Experiences Completing Tele-Consultations During the Coronavirus Disease (COVID-19) Pandemic
by: Arpit M. Chhabra, MD, et al.
Published: (2021-01-01) -
Use of Immunotherapy and Radiation Treatment in the Management of Metastatic Melanoma With Rhabdomyosarcomatous Differentiation
by: Apar Gupta, MD, MBA, et al.
Published: (2020-01-01) -
18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma
by: Ryan S. Youland, MD, et al.
Published: (2017-04-01) -
An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers
by: Yi Yu MD, et al.
Published: (2021-05-01)